{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:29:17Z","timestamp":1792218557747,"version":"4.4.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Monoclonal antibodies\u2014including rituximab, alemtuzumab, trastuzumab, bevacizumab, cetuximab, and panitumumab\u2014have improved the treatment of various malignancies. Although generally better tolerated with less toxicity than conventional anticancer agents, monoclonal antibodies may cause infusion-related reactions like other infusional agents. The incidence of infusion reactions varies by agent, but severe events occur only occasionally, mostly with the first or second infusion. Although the exact etiology of infusion reactions remains unclear, they may arise via either IgE- or non-IgE\u2013dependent mechanisms. There is a compelling clinical need to improve the risk assessment for severe infusion reactions. The recent identification of pre-existing IgE crossreacting with cetuximab, its association with severe reactions, and regional variation in the prevalence may provide a marker for high-risk assessment. Premedication with antihistamines, acetaminophen, and\/or corticosteroids is a common practice to prevent infusion reactions with all monoclonal antibodies. However, a recent observational study suggests that premedication may no longer be necessary after the second infusion of cetuximab if patients did not develop any symptoms with the first two infusions. Considering the heterogeneity of infusion reactions, clinicians need to recognize the underlying nature of these events in order to identify patients at risk as well as provide optimal prophylactic measures and management of symptoms.<\/jats:p>","DOI":"10.1634\/theoncologist.2008-0012","type":"journal-article","created":{"date-parts":[[2008,6,27]],"date-time":"2008-06-27T11:38:21Z","timestamp":1214566701000},"page":"725-732","source":"Crossref","is-referenced-by-count":232,"title":["Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy"],"prefix":"10.1093","volume":"13","author":[{"given":"Christine H.","family":"Chung","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine and Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2008,6,1]]},"reference":[{"key":"2021122208462620300_R1","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"The Oncologist"},{"key":"2021122208462620300_R2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1023\/A:1006341717398","article-title":"Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy","volume":"18","author":"Dillman","year":"1999","journal-title":"Cancer Metastasis Rev"},{"key":"2021122208462620300_R3","volume-title":"Common Terminology Criteria for Adverse Events v3.0. Publish date August 9, 2006","author":"National Cancer Institute","year":"2007"},{"key":"2021122208462620300_R4","first-page":"1373","article-title":"Cetuximab-associated infusion reactions: Pathology and management","volume":"20","author":"Patel","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"2021122208462620300_R5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2174\/1568011043352713","article-title":"Monoclonal antibodies in cancer therapy","volume":"4","author":"Gatto","year":"2004","journal-title":"Curr Med Chem Anticancer Agents"},{"key":"2021122208462620300_R6","volume-title":"ERBITUX\u00ae (cetuximab) [package insert]","year":"2007"},{"key":"2021122208462620300_R7","volume-title":"Vectibix\u00ae (panitumumab) [package insert]","year":"2007"},{"key":"2021122208462620300_R8","volume-title":"Avastin\u00ae (bevacizumab) [package insert]"},{"key":"2021122208462620300_R9","volume-title":"Rituxan\u00ae (rituximab) [package insert]","year":"2007"},{"key":"2021122208462620300_R10","volume-title":"Herceptin\u00ae (trastuzumab) [package insert]","year":"2006"},{"key":"2021122208462620300_R11","volume-title":"Taxotere\u00ae (docetaxel) injection concentrate [package insert]","year":"2007"},{"key":"2021122208462620300_R12","volume-title":"Taxol\u00ae (paclitaxel) injection [package insert]","year":"2003"},{"key":"2021122208462620300_R13","volume-title":"Paraplatin\u00ae (carboplatin aqueous solution) injection [package insert]","year":"2004"},{"key":"2021122208462620300_R14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs"},{"key":"2021122208462620300_R15","volume-title":"Campath\u00ae (alemtuzumab) [package insert]","year":"2007"},{"key":"2021122208462620300_R16","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122208462620300_R17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"2021122208462620300_R18","first-page":"5","article-title":"Anti-EGFR mechanism of action: Antitumor effect and underlying cause of adverse events","volume":"20","author":"Lenz","year":"2006","journal-title":"Oncology (Williston Park)"},{"key":"2021122208462620300_R19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122208462620300_R20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000055363","article-title":"Hypersensitivity reactions to carboplatin administration are common but not always severe: A 10-year experience","volume":"61","author":"Polyzos","year":"2001","journal-title":"Oncology"},{"key":"2021122208462620300_R21","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.bjc.6601155","article-title":"Hypersensitivity reactions related to oxaliplatin (OHP)","volume":"89","author":"Brandi","year":"2003","journal-title":"Br J Cancer"},{"key":"2021122208462620300_R22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/14740338.5.5.687","article-title":"Hypersensitivity reactions associated with oxaliplatin","volume":"5","author":"Saif","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"2021122208462620300_R23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdj042","article-title":"Hypersensitivity reactions to oxaliplatin: Experience in a single institution","volume":"17","author":"Siu","year":"2006","journal-title":"Ann Oncol"},{"issue":"1 suppl","key":"2021122208462620300_R24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1188\/07.CJON.S1.37-42","article-title":"Cytokine-release syndrome: Overview and nursing implications","volume":"11","author":"Breslin","year":"2007","journal-title":"Clin J Oncol Nurs"},{"key":"2021122208462620300_R25","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"2021122208462620300_R26","first-page":"105","article-title":"Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients","volume":"16","author":"Tonini","year":"2002","journal-title":"J Biol Regul Homeost Agents"},{"key":"2021122208462620300_R27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<247::AID-AJH9>3.0.CO;2-T","article-title":"Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"62","author":"Yang","year":"1999","journal-title":"Am J Hematol"},{"key":"2021122208462620300_R28","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1532\/IJH97.NA0504","article-title":"Acute tumor lysis syndrome induced by rituximab in diffuse large B-cell lymphoma","volume":"82","author":"Jabr","year":"2005","journal-title":"Int J Hematol"},{"key":"2021122208462620300_R29","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122208462620300_R30","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122208462620300_R31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1146\/annurev.immunol.21.120601.141103","article-title":"The biology of IgE and the basis for allergic disease","volume":"21","author":"Gould","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"2021122208462620300_R32","doi-asserted-by":"crossref","first-page":"S450","DOI":"10.1016\/j.jaci.2005.11.016","article-title":"IgE, mast cells, basophils, and eosinophils","volume":"117","author":"Prussin","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2021122208462620300_R33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000087574","article-title":"Mast cell-derived cytokine expression induced via Fc receptors and Toll-like receptors","volume":"87","author":"Okayama","year":"2005","journal-title":"Chem Immunol Allergy"},{"key":"2021122208462620300_R34","first-page":"S483","article-title":"Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: An updated practice parameter","volume":"115","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"2021122208462620300_R35","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N Engl J Med"},{"key":"2021122208462620300_R36","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2007.11.7812","article-title":"High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history","volume":"25","author":"O'Neil","year":"2007","journal-title":"J Clin Oncol"},{"issue":"suppl 12","key":"2021122208462620300_R37","first-page":"53","article-title":"Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: A benefit-risk update","volume":"27","author":"Kunkel","year":"2000","journal-title":"Semin Oncol"},{"issue":"suppl 2","key":"2021122208462620300_R38","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000055403","article-title":"Retrospective analysis of the safety of Herceptin\u00ae immunotherapy in metastatic breast cancer","volume":"61","author":"Cook-Bruns","year":"2001","journal-title":"Oncology"},{"key":"2021122208462620300_R39","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S1081-1206(10)61465-2","article-title":"Carboplatin desensitization","volume":"93","author":"Choi","year":"2004","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2021122208462620300_R40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2005.06.028","article-title":"Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: Standard protocol effective in 57 patients for 255 courses","volume":"99","author":"Lee","year":"2005","journal-title":"Gynecol Oncol"},{"key":"2021122208462620300_R41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00520-006-0159-x","article-title":"Successful management of infusion reaction accompanying the start of cetuximab therapy","volume":"15","author":"Melichar","year":"2007","journal-title":"Support Care Cancer"},{"key":"2021122208462620300_R42","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1067\/mai.2002.128689","article-title":"Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin)","volume":"110","author":"Melamed","year":"2002","journal-title":"J Allergy Clin Immunol"},{"issue":"18 suppl","key":"2021122208462620300_R43","article-title":"Infusion-related reactions (IRR) associated with cetuximab plus irinotecan treatment in patients with irinotecan-resistant metastatic colorectal cancer (mCRC): Findings from the MABEL study","volume":"25","author":"Siena","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"2021122208462620300_R44","article-title":"Cetuximab use without chronic antihistamine premedication","volume":"24","author":"Timoney","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2008-0012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2008-0012","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/6\/725\/41832041\/oncolo_13_6_725.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/13\/6\/725\/41832041\/oncolo_13_6_725.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T10:26:37Z","timestamp":1640168797000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/13\/6\/725\/6396678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2008,6,1]]},"published-print":{"date-parts":[[2008,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2008-0012","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2008,6,1]]},"published":{"date-parts":[[2008,6,1]]}}}